Castle Biosciences Inc (CSTL)vsNatera Inc (NTRA)
CSTL
Castle Biosciences Inc
$21.38
-2.73%
HEALTHCARE · Cap: $627.83M
NTRA
Natera Inc
$228.80
-3.06%
HEALTHCARE · Cap: $30.37B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 636% more annual revenue ($2.50B vs $339.92M). CSTL leads profitability with a -3.8% profit margin vs -9.1%. NTRA earns a higher WallStSmart Score of 31/100 (F).
CSTL
Avoid31
out of 100
Grade: F
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+58.2%
Fair Value
$77.42
Current Price
$21.38
$56.04 discount
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Revenue declined 4.9%
Trading at 18.4x book value
0.0% earnings growth
Weak financial health signals
ROE of -12.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CSTL
The strongest argument for CSTL centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : CSTL
The primary concerns for CSTL are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : NTRA
The primary concerns for NTRA are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
CSTL profiles as a turnaround stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA carries more volatility with a beta of 1.54 — expect wider price swings.
NTRA is growing revenue faster at 38.8% — sustainability is the question.
NTRA generates stronger free cash flow (18M), providing more financial flexibility.
Bottom Line
CSTL scores higher overall (31/100 vs 31/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Castle Biosciences Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Castle Biosciences Inc. is a leading diagnostics company dedicated to improving patient care through cutting-edge gene-expression profiling tests, specifically in the realm of skin cancer, with its flagship product, DecisionDx®-Melanoma. This innovative solution provides crucial insights into patient risk stratification, thus facilitating informed treatment decisions in melanoma management. With a steadfast commitment to precision medicine and a robust research and development framework, Castle Biosciences is strategically positioned to expand its portfolio and address pivotal clinical needs. By focusing on the complexities of oncology, the company aims to enhance clinical outcomes while driving significant value for shareholders.
Visit Website →Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?